Review




Structured Review

Cayman Chemical ttnpb
Ttnpb, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ttnpb/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
ttnpb - by Bioz Stars, 2026-02
90/100 stars

Images



Similar Products

93
MedChemExpress ttnpb
RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression <t>after</t> <t>IFN‐γ</t> <t>+TTNPB</t> and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).
Ttnpb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ttnpb/product/MedChemExpress
Average 93 stars, based on 1 article reviews
ttnpb - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Tocris tesr-e6+ with ttnpb
RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression <t>after</t> <t>IFN‐γ</t> <t>+TTNPB</t> and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).
Tesr E6+ With Ttnpb, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tesr-e6+ with ttnpb/product/Tocris
Average 90 stars, based on 1 article reviews
tesr-e6+ with ttnpb - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Cayman Chemical ttnpb
RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression <t>after</t> <t>IFN‐γ</t> <t>+TTNPB</t> and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).
Ttnpb, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ttnpb/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
ttnpb - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

93
Selleck Chemicals ttnpb
RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression <t>after</t> <t>IFN‐γ</t> <t>+TTNPB</t> and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).
Ttnpb, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ttnpb/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
ttnpb - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology 5 6 7 8 tetrahydro 5 5 8 8 tetramethyl 2 naphthalenyl 1 propenyl benzoic acid ttnpb santa cruz biotechnology
RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression <t>after</t> <t>IFN‐γ</t> <t>+TTNPB</t> and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).
5 6 7 8 Tetrahydro 5 5 8 8 Tetramethyl 2 Naphthalenyl 1 Propenyl Benzoic Acid Ttnpb Santa Cruz Biotechnology, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/5 6 7 8 tetrahydro 5 5 8 8 tetramethyl 2 naphthalenyl 1 propenyl benzoic acid ttnpb santa cruz biotechnology/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
5 6 7 8 tetrahydro 5 5 8 8 tetramethyl 2 naphthalenyl 1 propenyl benzoic acid ttnpb santa cruz biotechnology - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology 5 6 7 8 tetrahydro 5 5 8 8tetramethyl 2 naphthalenyl 1 propenyl benzoic acid ttnpb santa cruz biotechnology
RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression <t>after</t> <t>IFN‐γ</t> <t>+TTNPB</t> and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).
5 6 7 8 Tetrahydro 5 5 8 8tetramethyl 2 Naphthalenyl 1 Propenyl Benzoic Acid Ttnpb Santa Cruz Biotechnology, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/5 6 7 8 tetrahydro 5 5 8 8tetramethyl 2 naphthalenyl 1 propenyl benzoic acid ttnpb santa cruz biotechnology/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
5 6 7 8 tetrahydro 5 5 8 8tetramethyl 2 naphthalenyl 1 propenyl benzoic acid ttnpb santa cruz biotechnology - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology ttnpb
RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression <t>after</t> <t>IFN‐γ</t> <t>+TTNPB</t> and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).
Ttnpb, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ttnpb/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
ttnpb - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).

Journal: Advanced Science

Article Title: Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity

doi: 10.1002/advs.202509340

Figure Lengend Snippet: RA–RARα signaling induces CIITA‐dependent antigen‐presenting programming in mast cells. A) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). B) Flow cytometry analysis showing CD40 expression after IFN‐γ +TTNPB and IFN‐γ +Bexarotene treatment for 48 h ( n = 3). C) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). D) Flow cytometry analysis showing CD40 expression after IFN‐γ +AM580, IFN‐γ +Adapalene, and IFN‐γ +Palovarotene treatment for 48 h ( n = 3). E) Flow cytometry analysis showing HLA‐DR expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). F) Flow cytometry analysis showing CD40 expression after IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3). G) Flow cytometry analysis showing CMV antigen presentation by mast cells to CD4⁺ and CD8⁺ T cells under different treatments, with T cell activation assessed by 4‐1BB and TNF‐α expression. H) Volcano plot showing significantly differentially expressed genes between the IFN‐γ + RA treatment group and the IFN‐γ treatment alone group. I) The mRNA expression of CIITA after IFN‐γ, RA, IFN‐γ +RA, IFN‐γ + RA+ Ro 41‐5253 treatment for 48 h ( n = 3).

Article Snippet: The cells were then treated with 100 U mL −1 IFN‐γ (Propretech, #300‐02) (IFN‐γ group) or 100 U mL −1 IFN‐γ plus 50 nM RA (MeilunBio, #MB1302) (IFN‐γ + RA group) for 48 or 72 h. TTNPB (#HY‐15682), Bexarotene (#HY‐14171), AM580 (#HY‐10475), Adapalene (#HY‐B0091), Palovarotene (#HY‐14799), Ro 41‐5253 (#HY‐116248) were purchased from MCE.

Techniques: Flow Cytometry, Expressing, Immunopeptidomics, Activation Assay